Monte村 〜Did you go to university? http://acsh.org/cyproheptadine-online-order.pdf ancient buy apetamin cyproheptadine syrup inform please After splitting off its drug unit from the medical device portion of the company on Jan. 1, Abbott is clearly using this large-scale deal to further bolster its profile as a medical device manufacturer. According to the company’s press release, “The $500 million market for peripheral artery disease, a blockage in the leg arteries that affects about 27 million people in the U.S. and Europe, is fueled by rising obesity and diabetes rates.” This, combined with the fact that traditional heart stent sales continue to lag, makes the acquisition of IDEV particularly strategic for Abbott going forward.
〜[24879番地]
|